medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-23-47-51medalphabet-4649Research ArticleСтатьиПотенциальные предикторы рецидива акне после терапии системным изотретиноином: обзор литературыPotential predictors of acne relapse after systemic isotretinoin therapy: a literature reviewhttps://orcid.org/0009-0000-9044-0672КонстантиновскаяЕ. Е.KonstantinovskayaE. E.

Константиновская Екатерина Евгеньевна, соискатель кафедры дерматовенерологии и косметологии

Москва

Konstantinovskaya Ekaterina E., applicant at Dept of Dermatovenereology and Cosmetology

Moscow

katerinak.90@mail.ruhttps://orcid.org/0000-0003-4920-5288ОльховскаяК. Б.OlkhovskayaK. B.

Ольховская Кира Брониславовна, к.м.н., доцент кафедры дерматовенерологии и косметологии

Москва

Olkhovskaya Kira B., PhD Med, associate professor at Dept of Dermatovenereology and Cosmetology

Moscow

olhovskaya_kira@mail.ruhttps://orcid.org/0009-0003-7468-998XПроценкоА. Н.ProtsenkoA. N.

Проценко Алексей Николаевич, к.м.н., доцент кафедры дерматовенерологии имени академика Ю.К. Скрипкина Института клинической медицины

Москва

Protsenko Alexey N., PhD Med, associate professor at Dept of Dermatovenereology named after Academician Yu.K. Skripkin of the Institute of Clinical Medicine

Moscow

anprotsenko1972@yandex.ruФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияCentral State Medical Academy of the Administrative Department of the President of the Russian FederationRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России (Пироговский университет)РоссияN.I. Pirogov Russian National Research Medical University (Pirogov University)Russian Federation202511112025123Дерматология (2)4751Copyright © Константиновская Е.Е., Ольховская К.Б., Проценко А.Н., 20252025Константиновская Е.Е., Ольховская К.Б., Проценко А.Н.Konstantinovskaya E.E., Olkhovskaya K.B., Protsenko A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4649

Рецидив акне после окончания терапии системным изотретиноином остается значимой клинической проблемой с частотой развития от 9% до 65%. В обзоре проанализированы существующие данные о потенциальных предикторах рецидива акне и о роли кумулятивной дозы и различных суточных дозировках системного изотретиноина в сохранении длительной ремиссии. Подчеркивается, что несопоставимость результатов различных исследований во многом обусловлена методологическими различиями (неоднородность выборок, отсутствие стандартизированного определения понятия «рецидив акне»). Статья акцентирует настоятельную потребность в унификации критериев рецидива при комплексной оценке прогностических факторов для создания персонифицированных подходов в лечении больных с акне с учетом индивидуальных рисков развития рецидива и оптимизации режимов дозирования системного изотретиноина.

Acne relapse following completion of systemic isotretinoin therapy remains a significant clinical problem, with recurrence rates ranging from 9% to 65%. This review analyzes existing data on potential predictors of acne relapse and the role of cumulative dose and various daily dosing regimens of systemic isotretinoin in maintaining long‑term remission. We emphasize that the lack of comparability in results across different studies is largely due to methodological differences (heterogeneous patient populations, the absence of a standardized definition for «acne relapse»). The article underscores the urgent need to unify relapse criteria for a comprehensive assessment of prognostic factors to create personalized treatment approaches for acne patients, taking into account the individual relapse risks and optimizing systemic isotretinoin dosing regimens.

акнерецидивизотретиноинрежимы дозированиясистемные ретиноидыacnerelapseisotretinoinsystemic retinoidsReferencesTuchayi S.M., Makrantonaki E., Ganceviciene R., et al. Acne vulgaris. Nat Rev Dis Primers. 2015; 1 (1): 15029. DOI:10.1038/nrdp.2015.29Tuchayi S.M., Makrantonaki E., Ganceviciene R., et al. Acne vulgaris. Nat Rev Dis Primers. 2015; 1 (1): 15029. DOI:10.1038/nrdp.2015.29Vos T., Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380 (9859): 2163–2196. DOI: 10.1016/s0140–6736(12)61729Vos T., Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380 (9859): 2163–2196. DOI: 10.1016/s0140–6736(12)61729Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020; 10 (1): 5754. DOI: 10.1038/s41598 020 62715 3Heng A.H.S., Chew F.T. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020; 10 (1): 5754. DOI: 10.1038/s41598-020-62715-3Woodie B.R., Holt I.N., Freking J.A., et al. Severity of acne vulgaris predicts maladaptive psychosocial perceptions and neuropsychiatric disorders: a case control study. Arch Dermatol Res. 2025; 317 (1): 597. DOI: 10.1007/s00403–025–04123 zWoodie B.R., Holt I.N., Freking J.A., et al. Severity of acne vulgaris predicts maladaptive psychosocial perceptions and neuropsychiatric disorders: a case control study. Arch Dermatol Res. 2025; 317 (1): 597. DOI: 10.1007/s00403–025–04123-zReynolds R.V., Yeung H., Cheng C.E., et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024; 90 (5): 1006. e1–1006.e30. DOI: 10.1016/j.jaad.2023.12.017Reynolds R.V., Yeung H., Cheng C.E., et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024; 90 (5): 1006. e1–1006.e30. DOI: 10.1016/j.jaad.2023.12.017Landis M.N. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020; 21 (3): 411–419. DOI: 10.1007/s40257 020 00508 0Landis M.N. Optimizing isotretinoin treatment of acne: update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol. 2020; 21 (3): 411–419. DOI: 10.1007/s40257-020-00508-0Круглова Л.С., Грязева Н.В., Тамразова А.В. Системное лечение среднетяжелых форм акне: патогенетически обоснованный выбор терапии. Медицинский алфавит. 2022; 8: 29–33. DOI: 10.33667/2078-5631-2022-8-29-33Kruglova L.S., Gryazeva N.V., Tamrazova A.V. Systemic treatment of moderate acne: pathogenetically substantiated choice of therapy. Medical alphabet. 2022; 8: 29 33. (In Russ.). DOI: 10.33667/2078-5631-2022-8-29-33Thiboutot D.M., Dréno B., Abanmi A., et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology. 2018; 78 (2): S1 S23.e1. DOI: 10.1016/j.jaad.2017.09.078Thiboutot D.M., Dréno B., Abanmi A., et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology. 2018; 78 (2): S1 S23.e1. DOI: 10.1016/j.jaad.2017.09.078Al Mutairi N., Manchanda Y., Nour Eldin O., Sultan A. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol. 2005; 4 (3): 369–373.Al Mutairi N., Manchanda Y., Nour Eldin O., Sultan A. Isotretinoin in acne vulgaris: a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol. 2005; 4 (3): 369–373.Quéreux G., Volteau C., N’Guyen J.M., Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006; 212 (2): 168–176. DOI: 10.1159/000090658Quéreux G., Volteau C., N’Guyen J.M., Dréno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006; 212 (2): 168–176. DOI: 10.1159/000090658Lehucher Ceyrac D., De La Salmonière P., Chastang C., Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology. 1999; 198 (3): 278–283. DOI: 10.1159/000018130Lehucher Ceyrac D., De La Salmonière P., Chastang C., Morel P. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology. 1999; 198 (3): 278–283. DOI: 10.1159/000018130White G.M., Chen W., Yao J., Wolde Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998; 134 (3): 376–378. DOI: 10.1001/archderm.134.3.376White G.M., Chen W., Yao J., Wolde Tsadik G. Recurrence rates after the first course of isotretinoin. Arch Dermatol. 1998; 134 (3): 376–378. DOI: 10.1001/archderm.134.3.376Demirci Saadet E. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris. Dermatologic Therapy. 2021; 34 (6): e15109. DOI: 10.1111/dth.15109Demirci Saadet E. Investigation of relapse rate and factors affecting relapse after oral isotretinoin treatment in patients with acne vulgaris. Dermatologic Therapy. 2021; 34 (6): e15109. DOI: 10.1111/dth.15109Lai J., Barbieri J.S. Acne relapse and isotretinoin retrial in patients with acne. JAMA Dermatol. 2025; 161 (4): 367. DOI: 10.1001/jamadermatol.2024.5416Lai J., Barbieri J.S. Acne relapse and isotretinoin retrial in patients with acne. JAMA Dermatol. 2025; 161 (4): 367. DOI: 10.1001/jamadermatol.2024.5416Morales Cardona C.A., Sánchez Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr. 2013; 104 (1): 61–66. DOI: 10.1016/j.ad.2012.05.004Morales Cardona C.A., Sánchez Vanegas G. Acne relapse rate and predictors of relapse following treatment with oral isotretinoin. Actas Dermosifiliogr. 2013; 104 (1): 61–66. DOI: 10.1016/j.ad.2012.05.004Перламутров Ю. Н., Ольховская К. Б., Соловьев А. М., Ляпон А. О. Определение ключевых прогностических факторов развития рецидива акне после терапии системным изотретиноином. Consilium Medicum. 2022; 24 (8): 529–533. DOI: 10.26442/20751753.2022.8.201753Perlamutrov Yu.N., Olkhovskaya K.B., Soloviev A.M., Lyapon A.O. Determination of key prognostic factors for the development of acne recurrence after therapy with systemic isotretinoin. Consilium Medicum. 2022; 24 (8): 529–533. (In Russ.). DOI: 10.26442/20751753.2022.8.201753Azoulay L., Oraichi D., Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case control study. Br J Dermatol. 2007; 157 (6): 1240–1248. DOI: 10.1111/j.1365–2133.2007.08250.xAzoulay L., Oraichi D., Bérard A. Isotretinoin therapy and the incidence of acne relapse: a nested case control study. Br J Dermatol. 2007; 157 (6): 1240–1248. DOI: 10.1111/j.1365–2133.2007.08250.xLiu A., Yang D. J., Gerhardstein P. C., Hsu S. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients. J Drugs Dermatol. 2008; 7 (10): 963–966.Liu A., Yang D. J., Gerhardstein P. C., Hsu S. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients. J Drugs Dermatol. 2008; 7 (10): 963–966.Borghi A., Mantovani L., Minghetti S., et al. Low cumulative dose isotretinoin treatment in mild to moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011; 25 (9): 1094–1098. DOI: 10.1111/j.1468–3083.2010.03933.xBorghi A., Mantovani L., Minghetti S., et al. Low cumulative dose isotretinoin treatment in mild to moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol. 2011; 25 (9): 1094–1098. DOI: 10.1111/j.1468–3083.2010.03933.xColoe J., Du H., Morrell D.S. Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne? J Am Acad Dermatol. 2011; 65 (2): 422–423. DOI: 10.1016/j.jaad.2010.06.025Coloe J., Du H., Morrell D.S. Could higher doses of isotretinoin reduce the frequency of treatment failure in patients with acne? J Am Acad Dermatol. 2011; 65 (2): 422–423. DOI: 10.1016/j.jaad.2010.06.025Blasiak R.C., Stamey C.R., Burkhart C.N., et al. High dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013; 149 (12): 1392. DOI: 10.1001/jamadermatol.2013.6746Blasiak R.C., Stamey C.R., Burkhart C.N., et al. High dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris. JAMA Dermatol. 2013; 149 (12): 1392. DOI: 10.1001/jamadermatol.2013.6746Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Aust J Dermatology. 2010; 51 (4): 248–253. DOI: 10.1111/j.1440–0960.2010.00657.xRademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Aust J Dermatology. 2010; 51 (4): 248–253. DOI: 10.1111/j.1440–0960.2010.00657.xNascimento C.R., Martins A.L.G.P., Milagres S.P., Bastazini Jr I. Acne recurrence after treatment with oral isotretinoin: 5 year follow up. Surg Cosmet Dermatol. 2011; 3 (3): 188–191.Nascimento C.R., Martins A.L.G.P., Milagres S.P., Bastazini Jr I. Acne recurrence after treatment with oral isotretinoin: 5 year follow up. Surg Cosmet Dermatol. 2011; 3 (3): 188–191.Haryati I., Jacinto S.S. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol. 2005; 44 (12): 999 1001. DOI: 10.1111/j.1365–4632.2005.02284.xHaryati I., Jacinto S.S. Profile of acne patients in the Philippines requiring a second course of oral isotretinoin. Int J Dermatol. 2005; 44 (12): 999 1001. DOI: 10.1111/j.1365–4632.2005.02284.xLee J.W., Yoo K.H., Park K.Y., et al. Effectiveness of conventional, low dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011; 164 (6): 1369–1375. DOI: 10.1111/j.1365–2133.2010.10152.xLee J.W., Yoo K.H., Park K.Y., et al. Effectiveness of conventional, low dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study. Br J Dermatol. 2011; 164 (6): 1369–1375. DOI: 10.1111/j.1365–2133.2010.10152.xRademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016; 55 (5): 518–523. DOI: 10.1111/ijd.12942Rademaker M. Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris. Int J Dermatol. 2016; 55 (5): 518–523. DOI: 10.1111/ijd.12942Sadeghzadeh Bazargan A., Ghassemi M., Goodarzi A., et al. Systematic review of low dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021; 34 (1): e14438. DOI: 10.1111/dth.14438Sadeghzadeh Bazargan A., Ghassemi M., Goodarzi A., et al. Systematic review of low dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther. 2021; 34 (1): e14438. DOI: 10.1111/dth.14438Al Muqarrab F., Almohssen A. Low dose oral isotretinoin for the treatment of adult patients with mild to moderate acne vulgaris: Systematic review and meta analysis. Dermatologic Therapy. 2022; 35 (4): e15311. DOI: 10.1111/dth.15311Al Muqarrab F., Almohssen A. Low dose oral isotretinoin for the treatment of adult patients with mild to moderate acne vulgaris: Systematic review and meta analysis. Dermatologic Therapy. 2022; 35 (4): e15311. DOI: 10.1111/dth.15311Kassem B., Ismail M., Hassan F. Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study. Dermatologic Therapy. 2022; 35 (12): e15974. DOI: 10.1111/dth.15974Kassem B., Ismail M., Hassan F. Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study. Dermatologic Therapy. 2022; 35 (12): e15974. DOI: 10.1111/dth.15974Goulden V., Clark S.M., McGeown C., Cunliffe W.J. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997; 137 (1): 106–108.Goulden V., Clark S.M., McGeown C., Cunliffe W.J. Treatment of acne with intermittent isotretinoin. Br J Dermatol. 1997; 137 (1): 106–108.Cakir G.A., Erdogan F.G., Gurler A. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. Int J Dermatol. 2013; 52 (3): 371–376. DOI: 10.1111/j.1365–4632.2012.05691.xCakir G.A., Erdogan F.G., Gurler A. Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. Int J Dermatol. 2013; 52 (3): 371–376. DOI: 10.1111/j.1365–4632.2012.05691.xBettoli V., Borghi A., Zauli S., et al. Maintenance therapy for acne vulgaris: efficacy of a 12 month treatment with adapalene benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology. 2013; 227 (2): 97–102. DOI: 10.1159/000350820Bettoli V., Borghi A., Zauli S., et al. Maintenance therapy for acne vulgaris: efficacy of a 12 month treatment with adapalene benzoyl peroxide after oral isotretinoin and a review of the literature. Dermatology. 2013; 227 (2): 97–102. DOI: 10.1159/000350820Truchuelo M.T., Jiménez N., Mavura D., Jaén P. Assessment of the efficacy and safety of a combination of 2 topical retinoids (RetinSphere) in maintaining post treatment response of acne to oral isotretinoin. Actas Dermosifiliogr. 2015; 106 (2): 126–132. DOI: 10.1016/j.ad.2014.09.001Truchuelo M.T., Jiménez N., Mavura D., Jaén P. Assessment of the efficacy and safety of a combination of 2 topical retinoids (RetinSphere) in maintaining post treatment response of acne to oral isotretinoin. Actas Dermosifiliogr. 2015; 106 (2): 126–132. DOI: 10.1016/j.ad.2014.09.001

The authors declare that there are no conflicts of interest present.